How can artificial intelligence optimize value-based contracting?

被引:0
作者
Jose Luis Poveda
Rosa Bretón-Romero
Carlos Del Rio-Bermudez
Miren Taberna
Ignacio H. Medrano
机构
[1] University and Polytechnic Hospital La Fe,Pharmacy Department, Drug Clinical Area
[2] Savana Research SL,undefined
[3] MedSavana SL,undefined
来源
Journal of Pharmaceutical Policy and Practice | / 15卷
关键词
D O I
暂无
中图分类号
学科分类号
摘要
Efforts in the pharmaceutical market have been aimed at ensuring that the benefits obtained from the introduction of new therapies justify the associated costs. In recent years, drug payment models in healthcare have undergone a dramatic shift from focusing on volume (i.e., size of the target clinical population) to focusing on value (i.e., drug performance in real-world settings). In this context, value-based contracts (VBCs) were designed to align the payment of a drug to its clinical performance outside clinical trials by evaluating the effectiveness using real-word evidence (RWE). Despite their widespread implementation, different factors jeopardize the application of VBCs to most marketed drugs in a near future, including the need for easily measurable and relevant outcomes associated with clinical improvements, and access to a large patient population to assess said outcomes. Here, we argue that the extraction and analysis of massive amounts of RWE captured in patients’ electronic health records (EHRs) will circumvent these issues and optimize negotiations in VBCs. Particularly, the use of Natural Language Processing (NLP) has proven successful in the analysis of structured and unstructured clinical information in EHRs in multicenter research studies. Thus, the application of NLP to analyze patient-centered information in EHRs in the context of innovative contracting can be utterly beneficial as it enables the real-time evaluation of treatment response and financial impact in real-world settings.
引用
收藏
相关论文
共 89 条
  • [1] Kee A(2019)Value-based contracting: challenges and opportunities Am J Med Qual 34 615-617
  • [2] Maio V(2018)Factors influencing the implementation of value-based contracting between pharmaceutical manufacturers and payers J Clin Pathways 4 27-30
  • [3] Buyse M(2020)Is there a future for value-based contracting? Value Health 23 416-417
  • [4] Carter S(2021)Impact of real-world data on market authorization, reimbursement decision & price negotiation Ther Innov Regul Sci 55 228-238
  • [5] Sarnataro K(2020)Managed entry agreements: policy analysis from the European perspective Value Health 23 425-433
  • [6] Cohen JP(2021)The use of innovative payments mechanisms for gene therapies in Europe and the USA Regen Med 16 405-422
  • [7] Pulini AA(2018)Los contratos de riesgo compartido en el sistema nacional de salud; percepciones de los profesionales sanitarios Rev Esp Salud Pública 92 e1-e20
  • [8] Caetano GM(2019)Data rich, information poor: can we use electronic health records to create a learning healthcare system for pharmaceuticals? Clin Pharmacol Ther 105 912-922
  • [9] Clautiaux H(2003)Pharmacist intervention documentation in US health care systems Hosp Pharm 38 1141-1147
  • [10] Vergeron L(2019)ASHP national survey of pharmacy practice in hospital settings: monitoring and patient education-2018 Am J Health Syst Pharm 76 1038-1058